Article

Defining the role of neuroimaging in normal-tension glaucoma

San Francisco - Debate continues over whether to perform neuroimaging in patients with typical normal-tension glaucoma (NTG), but there are warning signs that should prompt ordering magnetic resonance imaging (MRI) with gadolinium, said Christopher A. Girkin, MD, MPH, associate professor of ophthalmology and director, glaucoma service, Callahan Eye Foundation Hospital, University of Alabama at Birmingham.

San Francisco - Debate continues over whether to perform neuroimaging in patients with typical normal-tension glaucoma (NTG), but there are warning signs that should prompt ordering magnetic resonance imaging (MRI) with gadolinium, said Christopher A. Girkin, MD, MPH, associate professor of ophthalmology and director, glaucoma service, Callahan Eye Foundation Hospital, University of Alabama at Birmingham.

Although results of several studies could not establish a cost benefit for routine imaging, in a trial reported by Ahmed et al. in 2002, cranial MRI revealed significant lesions compressing the anterior visual pathway in 4 of 62 patients with NTG versus none of 70 patients with primary open-angle glaucoma.

“Those results were somewhat surprising, but overall it seems neuroimaging in routine cases has low yield and questionable benefit so that further workup should focus only on cases that are atypical and vision-threatening,” Dr. Girkin said.

There are several signs of nonglaucomatous neuropathy that signal a need for further workup. Those consist of visual field loss that is out of proportion to optic disc changes; rim pallor greater in extent than the degree of cupping; central vision loss; color vision defect; vertically aligned visual field defects; neurologic fields that respect the vertical meridian; other cranial neuropathies; and a relative afferent pupillary defect that does not correspond to the degree of asymmetry in the visual field.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.